QuantaLife Announces Launch of Droplet Digital(TM) PCR System

WASHINGTON, Nov. 2, 2010 /PRNewswire/ -- QuantaLife, Inc. announced today at the 60th Annual American Society of Human Genetics Meeting the launch of their Droplet Digital PCR system. The system, which includes a droplet generator and a droplet reader, quantifies DNA molecules using the company's patented high-resolution, Droplet Digital PCR technology a 3rd generation PCR technology that enables single-molecule resolution of target sequences.

Droplet Digital PCR uses microfluidics to partition each sample into 20,000 to millions of one-nanoliter droplets, each of which contains a separate PCR. The droplets are streamed in single file past a detector to count the negative and positive reactions.

The QuantaLife system introduces a new era of high performance PCR testing. The system detects slight differences in gene copy number (i.e., 6 copies from 5), or a 10% difference in mRNA expression. There is no need for a standard. The system can read 48 samples per hour.

Serge Saxonov, Ph.D, Vice President of Application Development at QuantaLife will present results obtained using the QuantaLife system at the ASHG meeting. The seminar titled "Introducing the 3rd Generation of PCR: droplet digital PCR A New System for CNV Detection," will be held Friday, November 5, 2010 at 12:30 pm at the Grand Hyatt Washington, Lafayette Room, 1000 H Street NW, Washington, DC.

More information about QuantaLife and the Droplet Digital PCR system is available at www.quantalife.com.

About QuantaLife

QuantaLife has developed the 3rd generation of PCR technology that quantifies DNA molecules by Droplet Digital PCR . Droplet Digital PCR provides an absolute measure of target molecules with unrivaled quantitative resolution and sensitivity. Applications include copy number variation (CNV), mutation detection, and gene expression analysis. Our mission is to provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease.

Contact:

Mike Lucero

QuantaLife, Inc.

+1-650-823-6366



SOURCE QuantaLife, Inc.

MORE ON THIS TOPIC